Moreover, in a randomized controlled trial, liraglutide treatment increased plasma levels of the anti-inflammatory and antidiabetic adipokine adiponectin, which is ordinarily reduced in T2DM [43] compared to glimepiride treatment [44]. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.